Hyphens Pharma International (SGX:1J5) granted Louis Widmer rights to commercialize Cerapro MED Skin Barrier Cream to cover six European countries, according to a Monday filing with the Singapore Exchange.
Under the agreement with the Switzerland-based cosmetics and pharmaceutical firm, the company will receive an upfront fee and customary royalties on sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.